IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Cano et al.

Serial No.:

09/612,925

Filing Date: July 10, 2000

Title:

EXPRESSION SYSTEM OF HETEROLOGOUS ANTIGENS AS FUSION

PROTEIN\$

Examiner:

Devi, S.

Art Unit:

1645

Attorney Docket No.: LEXSA P-13 div2

Commissioner for Patents Washington, DC 20231

REQUEST UNDER 37 CFR 1.821(e)

Applicants respectfully request that the enclosed paper copy of the Sequence Listing be entered into the Specification. Please cancel all previously submitted paper copies.

The paper copy of the Sequence Listing submitted herewith is identical to the computer readable copy of the Sequence Listing filed in the parent application, Serial No. 08/930,917, filed September 16, 1997. The content of the paper copy and the computer readable copy are the same. No new matter has been added.

In accordance with 37 CFR 1.821(e), please use the last-filed computer readable form filed in the parent application, Serial No. 08/930,917, as the computer readable form for the instant application, Serial No. 09/612,925. The Patent and Trademark Office is authorized to take all necessary steps to advance and perfect this Request.

The following is a record of the facts underlying this Request.

On or around February 3, 2003, Attorney for Applicants was advised by the Examiner that the CRF copy of the Sequence Listing timely filed on October 16, 2002, was "unreadable." Attorney for Applicant consistently takes great pains to ensure that any Sequence Listing in CRF is undamaged and readable at the time of deposit with the U.S. Postal Service, especially in light of the on-going special requirements related to the receipt of CRF Sequence Listings at the U.S.P.T.O.

In a subsequent teleconference between Attorney for Applicants, the Examiner, and S.P.E. Lowe on March 12, 2003, it was resolved that the CRF copy of the Sequence Listing from the parent application would be used in the instant application, thus precipitating this Request.

As the Response filed on October 16, 2002 was both timely filed and fully compliant with the requirements of 37 C.F.R. 1.821-1.825 at the time of deposit with the U.S. Postal Service, Applicants submit that no fee is required to file this Request.

The Commissioner is authorized to charge any necessary fees or credit any overpayments to Deposit Account No. 10-0100 for Lackenbach Siegel, LLP.

Date: March 12, 2003

Respectfully submitted, LACKENBACH SIEGEL, LLP One Chase Road Scarsdale, NY 10583

(914) 723-4300

Thomas Blankinship Reg. No. 39,909

LACKENBACH SIEGEL, LLP

One Chase Road Scarsdale, NY, 10583 U.S.A.

FAX RECEIVED

MAR 1 3 2003

GROUP 1600

(914) 723-4300 Phone:

(914) 723-4301 Fax: mail@lslip.com E-Mail:

FACSIMILE COVER SHEET

OFFICIAL

Date:

March 12, 2003

To:

Examiner S. Devi

ART UNIT 1645

Facsimile No.: 703 308-4242

From:

Thomas Blankinship

Pages (including cover sheet): 24

Re:

U.S. Patent Application No. 09/612,925 for

EXPRESSION SYSTEM OF HETEROLOGOUS ANTIGENS AS FUSION

PROTEINS

Atty. Ref.:

LEXSA P-13 div 2

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being transmitted to the attention of Examiner S. Devi of Art Unit 1645 at group fax phone number (703) 308-4242 on March 12, 2003 in accordance with 37 CFR 1.6(d).

March 12, 2003 /

Date

Thomas Blankinshir

CONFIDENTIAL: This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, or have encountered any problem in receiving it, please notify us immediately by telephone. Thank you.